Search
Filter Results
Displaying 1151–1160 of 1172 results
-
Aug 4, 2015
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
Research News40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Jul 28, 2015
First AMD Patient Receives Argus II Bionic Retina
Research NewsA pioneering, 80-year-old named Ray Flynn is the first AMD patient to receive the Argus II, and he is already reporting that he can see things better in his garden.
-
Jul 16, 2015
Gene Therapy Strengthens the Retina's Connection to the Brain
Research NewsWhat happens to the brain when the eye is enabled to see through gene therapy? Would the brain and eye restart their partnership? We now know the answer is yes.
-
Apr 15, 2015
Beacon StoriesAn interview with Louis Posen, record label founder and retinitis pigmentosa patient.
-
Mar 20, 2015
Beacon StoriesPeople with retinal disease describe their experiences “not looking blind.”
-
Oct 14, 2014
Changing Someone’s Life: A New Video Emphasizes the Need to Support FFB’s Mission
Beacon StoriesAllison Corona is one of 40 people with Leber congenital amaurosis who’ve benefitted from a gene therapy clinical trial.
-
Sep 10, 2014
Ready for the Spotlight: Rebecca Alexander Shares Her Story of Living with Usher Syndrome
Beacon Stories“…the best thing is to reach out and network, and access all the resources. The more invested you are in what’s out there, the more you get back.”
-
Jun 26, 2014
Lighting a Candle: The Author of a New Memoir Shares the Highs and Lows of Vision Loss
Beacon StoriesNicole Simpson, author of “Now I See You,” shares her experience with retinitis pigmentosa.
-
Apr 21, 2014
Flight4Sight: A Man with Usher Syndrome Travels Around the Globe
Beacon StoriesThere’s nothing like a sense of urgency to turn what seems like a crazy idea into reality.
-
Dec 12, 2013
Foundation Chairman, Gordon Gund, Interviewed on Forbes.com
Beacon StoriesThe driving force behind the Foundation’s considerable advances covers those, as well as other compelling subjects, during a 27-minute Q&A.